Circulating tumor DNA (ctDNA) status and clinical outcomes in patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL) in the POLARIX study.

被引：0
|
作者：
Herrera, Alex Francisco
Tracy, Samuel
Sehn, Laurie Helen
Jardin, Fabrice
Lenz, Georg
Trneny, Marek
Salles, Gilles A.
Flowers, Christopher
Tilly, Herve
Sharman, Jeff Porter
Friedberg, Jonathan W.
Balasubramanian, Sandhya
Raghavan, Vibha
Hirata, Jamie H.
Lee, Calvin
Jiang, Yanwen
Morschhauser, Franck
机构：
[1] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA
[2] Ctr Henri Becquerel, Rouen, France
[3] Univ Rouen, Rouen, France
[4] Univ Hosp Munster, Munster, Germany
[5] Charles Univ Prague, Gen Hosp, Prague, Czech Republic
[6] Mem Sloan Kettering Canc Ctr, New York, NY USA
[7] Univ Texas MD Anderson Canc Ctr Houston, Houston, TX USA
[8] Willamette Valley Canc Inst & Res Ctr, US Oncol Res, Eugene, OR USA
[9] Univ Rochester, Wilmot Canc Inst, Rochester, NY USA
[10] Hoffmann Roche Ltd, Mississauga, ON, Canada
[11] Univ Lille, Ctr Hosp Univ, Lille, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7523
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Monitoring of Circulating Tumor DNA As Minimal Residual Disease in Diffuse Large B-Cell Lymphoma
    Roschewski, Mark
    Dunleavy, Kieron
    Pittaluga, Stefania
    Kong, Katie
    Shovlin, Margaret
    Jaffe, Elaine S.
    Staudt, Louis M.
    Lai, Catherine
    Chen, Clara C.
    Zheng, Jianbiao
    Willis, Thomas D.
    Faham, Malek
    Wilson, Wyndham H.
    BLOOD, 2014, 124 (21)
  • [42] Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
    Kurtz, David M.
    Scherer, Florian
    Jin, Michael C.
    Soo, Joanne
    Craig, Alexander F. M.
    Esfahani, Mohammad Shahrokh
    Chabon, Jacob J.
    Stehr, Henning
    Liu, Chih Long
    Tibshirani, Robert
    Maeda, Lauren S.
    Gupta, Neel K.
    Khodadoust, Michael S.
    Advani, Ranjana H.
    Levy, Ronald
    Newman, Aaron M.
    Duehrsen, Ulrich
    Huettmann, Andreas
    Meignan, Michel
    Casasnovas, Rene-Olivier
    Westin, Jason R.
    Roschewski, Mark
    Wilson, Wyndham H.
    Gaidano, Gianluca
    Rossi, Davide
    Diehn, Maximilian
    Alizadeh, Ash A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) : 2845 - +
  • [43] Analysis of clinical characteristics and outcome of patients with previously untreated diffuse large B-cell lymphoma and renal involvement in the rituximab era
    Lehners, N.
    Herth, I
    Egerer, G.
    Ho, A. D.
    Witzens-Harig, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 261 - 261
  • [44] Analysis of clinical characteristics and outcome of patients with previously untreated diffuse large B-cell lymphoma and renal involvement in the rituximab era
    Lehners, Nicola
    Kraemer, Isabelle
    Schwarzbich, Mark-Alexander
    Ho, Anthony D.
    Witzens-Harig, Mathias
    LEUKEMIA & LYMPHOMA, 2016, 57 (11) : 2619 - 2625
  • [45] Functional Status and Therapy for Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Population-Based Study
    Di, Mengyang
    Keeney, Tamra
    Belanger, Emmanuelle
    Panagiotou, Orestis A.
    Olszewski, Adam J.
    BLOOD, 2020, 136
  • [46] Consequences of immune defects in patients with diffuse large B-cell lymphoma (DLBCL)
    Flatman, Katarina
    Morfett, Samuel
    Ahearne, Matthew
    Allchin, Rebecca
    Balotis, Constantine
    Kennedy, Ben
    Ladani, Sapna
    Miall, Fiona
    Jayne, Sandrine
    Walter, Harriet
    Dyer, Martin
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 189 - 189
  • [47] Mutational Landscape of Diffuse Large B-Cell Lymphoma (DLBCL) in Mexican Patients
    Candelaria, Myrna
    Gutierrez-Hernandez, Olga
    Diaz-Chavez, Jose
    Cerrato, Dennis
    Gutierrez-Ramirez, Francisco J.
    Aviles, Alejandro
    BLOOD, 2023, 142
  • [48] Initial results of a pilot study of epratuzumab and rituximab in combination with CHOP chemotherapy (ER-CHOP) in previously untreated patients with diffuse large B-cell lymphoma (DLBCL).
    Micallef, IN
    Kahl, BS
    Gayko, U
    Cesano, A
    Ansell, SM
    Geyer, S
    Inwards, DJ
    Maurer, MJ
    Horning, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 577S - 577S
  • [49] The POLARIX Study: Polatuzumab Vedotin With Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone vs Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 10 - 11
  • [50] Baseline tumor volume affects rituximab pharmacokinetics in patients with diffuse large B-cell lymphoma (DLBCL)
    Tout, M.
    Cartron, G.
    Casasnovas, O.
    Meignan, M.
    Paintaud, G.
    Ternant, D.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2015, 29 : 8 - 8
12345